BioSpace News Archive

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapeutic drugs for cancer, announced today its financial results for the three months ended December 31, 2023 and provided a business update.

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, today reported unaudited financial results for its third quarter ended December 31, 2023, and recent business highlights.

Erasca, Inc. today announced two clinical trial collaboration and supply agreements (CTCSAs) with Novartis (NYSE: NVS) for the MEK inhibitor trametinib (MEKINIST®).

Tonix Pharmaceuticals Holding Corp. held a key opinion leader (KOL) webinar to discuss the positive Phase 3 data of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, and the path to file for FDA approval in the second half of 2024.

Vessi Medical Ltd. (“Vessi”) announced today that it has closed a Series A financing round of $16.5 million for its cryotherapy technology to treat Non Muscle Invasive Bladder Cancer (“NMIBC”).

SkinCure Oncology today announced receipt of a patent from the U.S. Patent and Trademark Office for a new image-guided technology that will be the fourth generation of SRT.

THINK Surgical, Inc. announced that it will enter into a new Collaboration Agreement with b-ONE Ortho Corporation.

Oncolytics Biotech® Inc. announced the expansion of enrollment for the anal cancer cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab in patients with second-line or later unresectable squamous cell carcinoma of the anal canal.

Replicate Bioscience today shared positive results from the Phase 1 trial of RBI-4000, its srRNA-based rabies vaccine.

Precision BioSciences, Inc. announced that the company has received pre-IND regulatory feedback from the U.S. Food and Drug Administration and ex-U.S. agencies.